Subscribe To
jounce therapeutics announces closing of tender offer
Stockholders to Receive $1.85 Per Share in Cash Plus Contingent Value Rights CAMBRIDGE, Mass., May 03, 2023 (GLOBE NEWSWIRE) — ...
May 4, 2023, 12:35 am
jounce (jnce) up 21% on accepting concentra's buyout offer
jounce Therapeutics (JNCE) is set to be acquired by Concentra Biosciences, spurning an all-share merger...
March 28, 2023, 1:44 pm
jounce (jnce) up 41% on buyout offer from concentra biosciences
jounce Therapeutics (JNCE) receives a proposal from Concentra Biosciences to acquire 100% equity stake ...
March 16, 2023, 1:00 pm
Tang capital partners now owns 10.2% of jounce therapeutics
Fintel reports that Tang Capital Partners has filed a 13D form with the SEC disclosing ownership of 5.30MM shares of ...
March 15, 2023, 10:30 pm
Why is jounce therapeutics (jnce) stock up 37% today?
jounce Therapeutics (NASDAQ: JNCE ) stock is climbing higher on Wednesday after getting an unexpected a...
March 15, 2023, 7:42 am
Lifshitz law pllc announces investigations of jnce, lnkb, ptrs, and indt
NEW YORK, Feb. 25, 2023 (GLOBE NEWSWIRE) — jounce Therapeutics, Inc. (NASDAQ: JNCE) Lifshitz Law PLLC...
February 26, 2023, 1:11 am
Why is jounce therapeutics (jnce) stock up 14% today?
jounce Therapeutics (NASDAQ: JNCE ) stock is on the rise Thursday after the company revealed merger pla...
February 23, 2023, 8:10 am
jounce: gilead's gs-1811 buyout allows a further bounce
jounce has recently announced that it has sold its entire rights to immunotherapy candidate GS-1181 to ...
December 29, 2022, 2:16 pm
Gilead (gild) to get full rights for jounce's immunotherapy
Gilead Sciences (GILD) is set to buy the remaining rights to the potential first-in-class immunotherapy GS-181 from ...
December 28, 2022, 12:21 pm
Why is jounce therapeutics (jnce) stock up 70% today?
jounce Therapeutics (NASDAQ: JNCE ) stock jumped after it sold rights to a cancer drug to Gilead Scienc...
December 28, 2022, 8:57 am
: jounce stock bounces more than 70% after gilead acquires immunotherapy drug
jounce Therapeutics Inc. JNCEshares jumped more than 70% in after-hours trading Tuesday, following an a...
December 27, 2022, 9:49 pm
Gilead buys out rights to cancer therapy from jounce for $67 mln
Gilead Sciences will buy all the remaining rights for an experimental cancer therapy, GS-1811, from jounce...
December 27, 2022, 9:34 pm
jounce stock bounces more than 70% after gilead acquires immunotherapy drug
jounce Therapeutics Inc. JNCE, -6.66% shares jumped more than 70% in after-hours trading Tuesday, follo...
December 27, 2022, 4:49 pm
jounce therapeutics, inc. (jnce) ceo richard murray on q2 2022 results - earnings call transcript
jounce Therapeutics, Inc. (NASDAQ:JNCE ) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Com...
August 5, 2022, 5:51 pm
jounce therapeutics, inc. (jnce) ceo richard murray on q1 2022 results - earnings call transcript
jounce Therapeutics, Inc. (NASDAQ:JNCE ) Q1 2022 Earnings Conference Call May 5, 2022 8:00 AM ET Compan...
May 7, 2022, 5:25 am
jounce therapeutics, inc. (jnce) ceo richard murray on q4 2021 results - earnings call transcript
jounce Therapeutics, Inc. (JNCE) CEO Richard Murray On Q4 2021 Results - Earnings Call Transcript...
March 2, 2022, 2:16 pm
jounce therapeutics, inc. (jnce) ceo richard murray on q4 2021 results - earnings call transcript
jounce Therapeutics, Inc. (JNCE) CEO Richard Murray On Q4 2021 Results - Earnings Call Transcript...
March 2, 2022, 2:16 pm
jounce therapeutics, inc. (jnce) ceo richard murray on q4 2021 results - earnings call transcript
jounce Therapeutics, Inc. (JNCE) CEO Richard Murray On Q4 2021 Results - Earnings Call Transcript...
March 2, 2022, 2:16 pm
jounce therapeutics, inc. (jnce) reports q4 loss, lags revenue estimates
jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of -156.52% and 100%, respect...
March 2, 2022, 9:57 am
jounce therapeutics, inc. (jnce) reports q4 loss, lags revenue estimates
jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of -156.52% and 100%, respect...
March 2, 2022, 9:57 am